Connect Biopharma presented additional data supporting rademikibart at the European Respiratory Society (ERS) Congress 2025. These data further expanded the understanding of rademikibart's potential efficacy for patients with moderate to severe asthma and COPD.
The presentations highlighted that rademikibart demonstrated rapid and significant improvement in lung function and asthma control. The greatest improvements were observed in patients with elevated baseline levels of key type 2 inflammatory markers.
Additionally, a significant reduction in annualized exacerbations was observed in patients with one or more elevated type 2 inflammatory markers at baseline. These analyses have helped refine clinical development plans and clinical site strategies for the ongoing Seabreeze STAT asthma and COPD studies, with topline data expected in the first half of 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.